{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:53:02Z","timestamp":1790016782105,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003491","name":"Herlev Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejca.2025.116095","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:18:24Z","timestamp":1762273104000},"page":"116095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Elevated levels of cleaved soluble forms of urokinase-type plasminogen activator receptor are associated with poor survival in advanced pancreatic cancer"],"prefix":"10.1016","volume":"231","author":[{"given":"R.L.","family":"Eefsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.J.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.Z.","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.M.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Calatayud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"H\u00f8yer-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2025.116095_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.ejca.2025.116095_bib2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"E.G.C.E.a. clinicalguidelines@esmo.org, Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2025.116095_bib3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"Digestives of, P. Intergroup, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ejca.2025.116095_bib4","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116095_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.612271","article-title":"Stroma involvement in pancreatic ductal adenocarcinoma: an overview focusing on extracellular matrix proteins","volume":"12","author":"Liot","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.ejca.2025.116095_bib6","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.biocel.2006.10.008","article-title":"Urokinase-type plasminogen activator","volume":"39","author":"Crippa","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.ejca.2025.116095_bib7","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/454368","article-title":"Complex regulation of the pericellular proteolytic microenvironment during tumor progression and wound repair: functional interactions between the serine protease and matrix metalloproteinase cascades","volume":"2012","author":"Wilkins-Port","year":"2012","journal-title":"Biochem Res Int"},{"issue":"4","key":"10.1016\/j.ejca.2025.116095_bib8","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1160\/TH05-01-0054","article-title":"Plasminogen activation and cancer","volume":"93","author":"Dano","year":"2005","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.ejca.2025.116095_bib9","first-page":"227","article-title":"The urokinase-system--role of cell proliferation and apoptosis","volume":"23","author":"Hildenbrand","year":"2008","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.ejca.2025.116095_bib10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fonc.2018.00024","article-title":"Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): diagnostic, prognostic, and therapeutic applications","volume":"8","author":"Mahmood","year":"2018","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.116095_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/biom12020152","article-title":"The urokinase plasminogen activation system in pancreatic cancer: prospective diagnostic and therapeutic targets","volume":"12","author":"Kumar","year":"2022","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.ejca.2025.116095_bib12","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.2353\/ajpath.2009.080785","article-title":"Amplification of the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically high-risk group","volume":"174","author":"Hildenbrand","year":"2009","journal-title":"Am J Pathol"},{"issue":"18","key":"10.1016\/j.ejca.2025.116095_bib13","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1158\/1078-0432.CCR-08-0096","article-title":"Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer","volume":"14","author":"Henic","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2025.116095_bib14","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3109\/0284186X.2010.491086","article-title":"Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients","volume":"49","author":"Lomholt","year":"2010","journal-title":"Acta Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2025.116095_bib15","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.lungcan.2011.05.008","article-title":"Urokinase receptor forms in serum from non-small cell lung cancer patients: relation to prognosis","volume":"74","author":"Almasi","year":"2011","journal-title":"Lung Cancer"},{"issue":"7-8","key":"10.1016\/j.ejca.2025.116095_bib16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.clinbiochem.2014.01.030","article-title":"Prognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patients","volume":"47","author":"Grunnet","year":"2014","journal-title":"Clin Biochem"},{"issue":"10","key":"10.1016\/j.ejca.2025.116095_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102377","article-title":"Circulating forms of urokinase-type plasminogen activator receptor in plasma can predict recurrence and survival in patients with urothelial carcinoma of the bladder","volume":"13","author":"Dohn","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.ejca.2025.116095_bib18","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/pros.21306","article-title":"Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer","volume":"71","author":"Almasi","year":"2011","journal-title":"Prostate"},{"issue":"19","key":"10.1016\/j.ejca.2025.116095_bib19","doi-asserted-by":"crossref","first-page":"12752","DOI":"10.1016\/S0021-9258(18)98963-5","article-title":"Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor","volume":"266","author":"Ellis","year":"1991","journal-title":"J Biol Chem"},{"issue":"19","key":"10.1016\/j.ejca.2025.116095_bib20","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2174\/1381612033454630","article-title":"Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor","volume":"9","author":"Ploug","year":"2003","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ejca.2025.116095_bib21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0065-2423(07)44003-3","article-title":"Urokinase receptor variants in tissue and body fluids","volume":"44","author":"Hoyer-Hansen","year":"2007","journal-title":"Adv Clin Chem"},{"issue":"12","key":"10.1016\/j.ejca.2025.116095_bib22","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.2174\/138945011797635902","article-title":"uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy","volume":"12","author":"Lund","year":"2011","journal-title":"Curr Drug Targets"},{"issue":"17","key":"10.1016\/j.ejca.2025.116095_bib23","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1093\/emboj\/19.17.4817","article-title":"Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis","volume":"19","author":"Zhou","year":"2000","journal-title":"EMBO J"},{"issue":"5","key":"10.1016\/j.ejca.2025.116095_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001216","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration","volume":"9","author":"Altman","year":"2012","journal-title":"PLoS Med"},{"issue":"8","key":"10.1016\/j.ejca.2025.116095_bib25","first-page":"232","article-title":"Identification of new biomarkers in patients with pancreatic cancer (BIOPAC): a study protocol of an open cohort study","volume":"11","author":"Chen I","year":"2019","journal-title":"J Cancer Sci Ther"},{"issue":"11","key":"10.1016\/j.ejca.2025.116095_bib26","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1373\/clinchem.2004.038232","article-title":"Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor","volume":"50","author":"Piironen","year":"2004","journal-title":"Clin Chem"},{"issue":"10","key":"10.1016\/j.ejca.2025.116095_bib27","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1373\/clinchem.2010.144410","article-title":"A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer","volume":"56","author":"Thurison","year":"2010","journal-title":"Clin Chem"},{"issue":"18","key":"10.1016\/j.ejca.2025.116095_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184599","article-title":"Inflammatory biomarker score identifies patients with six-fold increased risk of one-year mortality after pancreatic cancer","volume":"13","author":"Kjaergaard","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.ejca.2025.116095_bib29","first-page":"11683","article-title":"Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis","volume":"8","author":"Zhang","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"Pt 3","key":"10.1016\/j.ejca.2025.116095_bib30","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1042\/bj3580673","article-title":"Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor","volume":"358","author":"Hoyer-Hansen","year":"2001","journal-title":"Biochem J"},{"issue":"8","key":"10.1016\/j.ejca.2025.116095_bib31","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/carcin\/bgz033","article-title":"High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma","volume":"40","author":"Loosen","year":"2019","journal-title":"Carcinogenesis"},{"issue":"12","key":"10.1016\/j.ejca.2025.116095_bib32","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/bjs.11295","article-title":"Meta-analysis of recurrence pattern after resection for pancreatic cancer","volume":"106","author":"Tanaka","year":"2019","journal-title":"Br J Surg"},{"issue":"6","key":"10.1016\/j.ejca.2025.116095_bib33","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00280-020-04165-2","article-title":"The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis","volume":"86","author":"Ye","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2025.116095_bib34","doi-asserted-by":"crossref","DOI":"10.1177\/1177271917715443","article-title":"Prognostic impact of urokinase plasminogen activator receptor expression in pancreatic cancer: malignant versus stromal cells","volume":"12","author":"de Geus","year":"2017","journal-title":"Biomark Insights"},{"issue":"1","key":"10.1016\/j.ejca.2025.116095_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrm2821","article-title":"Regulation of cell signalling by uPAR","volume":"11","author":"Smith","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6917","key":"10.1016\/j.ejca.2025.116095_bib36","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"issue":"43","key":"10.1016\/j.ejca.2025.116095_bib37","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","article-title":"Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes","volume":"24","author":"McGuigan","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"12","key":"10.1016\/j.ejca.2025.116095_bib38","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.7150\/thno.12956","article-title":"First-in-human uPAR PET: imaging of cancer aggressiveness","volume":"5","author":"Persson","year":"2015","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.ejca.2025.116095_bib39","article-title":"Antibody-drug conjugates targeting the urokinase receptor (uPAR) as a possible treatment of aggressive breast cancer","volume":"8","author":"Harel","year":"2019","journal-title":"Antibodies (Basel)"},{"issue":"3","key":"10.1016\/j.ejca.2025.116095_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adq0513","article-title":"Targeting uPAR with an antibody-drug conjugate suppresses tumor growth and reshapes the immune landscape in pancreatic cancer models","volume":"11","author":"Metrangolo","year":"2025","journal-title":"Sci Adv"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925009815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925009815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T17:01:26Z","timestamp":1769792486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925009815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":40,"alternative-id":["S0959804925009815"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116095","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevated levels of cleaved soluble forms of urokinase-type plasminogen activator receptor are associated with poor survival in advanced pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116095"}}